Skip to main content
. 2021 May 21;100(20):e26046. doi: 10.1097/MD.0000000000026046

Table 1.

Characteristics of included trials.

Study country diagnostic criteria sample size (% female) treatment duration (weeks) treatment, n (dose range) Drug class used Criteria used to define symptom improvement following therapy
Hashash et al, 2008 Lebanon Rome III 25 (56.0) 2 F + M, 13(1 mg/day + 20 mg/day) Placebo, 12 antipsychotics and TCADs Patient-reported subjective feeling of global symptom relief
Tack et al, 2009 Belgium, Germany and The Netherlands Rome II 53 (66.0) 4 R137696, 29(6 mg/day) Placebo, 24 5-HT1A receptor agonists 30% improvement in patient assessment of upper gastrointestinal symptom severity
Miwa et al, 2009 Japan Rome II 150 (73.3) 4 Tandospirone, 75(30 mg/day) Placebo, 75 5-HT1A receptor agonists Patient-reported total abdominal symptom score of 0 or 1 on a modified gastrointestinal symptom rating scale
Braak et al, 2011 The Netherlands Rome II 38 (60.5) 8 Amitriptyline, 18(25 mg/day) Placebo, 20 TCADs 30% improvement in patient assessment of upper gastrointestinal symptom severity
Wu et al, 2011 Hong Kong, China Rome II 107 (80.4) 12 Imipramine, 55(50 mg/day) Placebo, 52 TCADs Patient-reported relief of global symptoms
Tack et al, 2012 Belgium Rome II 17 (76.5) 4 Buspirone, 7(30 mg/day) Placebo, 10 5-HT1A receptor agonists 30% improvement in patient-reported dyspepsia symptom severity
Tan et al, 2012 Hong Kong, China Rome II 193 (72.0) 8 Sertraline, 98(50 mg/day) Placebo, 95 SSRIs, Patient-reported relief of global symptoms
Tack et al, 2015 Belgium Rome III 34 (85.3) 8 Mirtazepine, 17(15 mg/day) Placebo, 17 tetracyclic antidepressants 30% improvement in patient-reported dyspepsia symptom severity
Talley et al, 2015 USA and Canada Rome II 292 (75.0) 12 Amitriptyline, 97(25-50 mg/day) escitalopram, 98(10 mg/day) Placebo, 97 TCADs SSRIs Patient-reported adequate relief of global symptoms for 50% of weeks during weeks 3–12
Kaosombatwattana U et al, 2018 Bangkok, Thailand Rome III 61(70.0) 8 Nortriptyline, 28(10 mg/day) Placebo, 33 TCADs 50% improvement in patient-reported dyspepsia symptom score